Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Dysfunctional Worry
- Sponsor
- Karolinska Institutet
- Enrollment
- 670
- Locations
- 1
- Primary Endpoint
- • Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this study is to investigate if a brief online-delivered cognitive-behavioral intervention can reduce the degree of dysfunctional worry related to the Covid-19 pandemic, compared to a wait-list control condition.
Detailed Description
Worries about the immediate and long-term consequences of the ongoing Covid-19 pandemic are largely justified in the current climate of uncertainty. However, dysfunctional worry, that is, pervasive worry that is disproportionate in its intensity or duration, and that significantly interferes with every-day problem-solving or goal-driven behavior, is clearly counterproductive. Research has also indicated that repeated media exposure to a community crisis can lead to increased anxiety and heightened stress responses, that can give a downstream effect on health, and misplaced health-protective and help-seeking behaviors which, in turn, may overburden health care facilities. There is an urgent need to develop a brief, scalable intervention to target such dysfunctional worry in the general population. The current randomized controlled trial will evaluate the feasibility and efficacy of a brief online-delivered cognitive behavioral intervention designed to target dysfunctional worry related to the Covid-19 pandemic. 670 individuals are randomized to intervention or to waiting-list. The hypothesis is that the brief self-guided intervention will show significant within-group reductions in self-rated worry from baseline (week 0) to post-treatment (week 3), and that these improvements will be larger than those seen in the wait-list control group. The wait-list group will be crossed over to receive the intervention after three weeks (post-treatment). All participants will be followed-up one month and one year after the end of the intervention.
Investigators
Erik Andersson
PhD, psychologist
Karolinska Institutet
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
• Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)
Time Frame: Basline (week 0), during treatment (week 1 and week 2), post treatment (week 3), at one-month after treatment and also one year follow up.
A 7-item self-rated scale to assess symtom severity of worry. Total score ranging from 0 to 21. Effects will be expressed as the change from baseline to last post-treatment value (Week 0-Week 3) period. Effects will also be assessed at one month and one year post-treatment.
Secondary Outcomes
- Patient Satisfaction Questionnaire (PSQ)(Post treatment (week 3))
- Adverse events (AE)(Post treatment (week 3))
- Intolerance of uncertainty Scale (IUS)(Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.)
- Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS)(Basline (week 0), during treatment (week 1 and week 2), post treatment (week 3), at one-month after treatment and also one year follow up.)
- Insomnia Severity Index (ISI)(Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.)
- Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS)(Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.)
- Montgomery Åsberg Depression Rating Scale - Self report (MADRS-S)(Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.)